Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-06-19
2007-06-19
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S375000, C548S218000, C540S229000
Reexamination Certificate
active
10510620
ABSTRACT:
The present invention relates to derivatives of 1-oxa-3-aza-dibenzoazulene class, to their pharmacologically acceptable salts and solvates, to processes and intermediates for the preparation thereof as well as to their antiinflammatory actions, especially to the inhibition of tumour necrosis factor-α (TNF-α) production and the inhibition of interleukin-1 (IL-1) production as well as to their analgetic action.
REFERENCES:
patent: 3711489 (1973-01-01), Lombardino
patent: 3838123 (1974-09-01), Viterbo et al.
patent: 4198421 (1980-04-01), Cherkofsky et al.
patent: 2005/0130964 (2005-06-01), Mercep et al.
patent: 2005/0131056 (2005-06-01), Mercep et al.
patent: 2005/0137249 (2005-06-01), Mercep et al.
patent: 2005/0148576 (2005-07-01), Mercep et al.
patent: 2005/0148577 (2005-07-01), Mercep et al.
patent: 2005/0171091 (2005-08-01), Mercep et al.
patent: 2005/0182126 (2005-08-01), Mercep et al.
patent: 2005/0209191 (2005-09-01), Mercep et al.
patent: 2005/0227963 (2005-10-01), Mercep et al.
patent: 2006/0069149 (2006-03-01), Mercep et al.
patent: 2006/0111340 (2006-05-01), Mercep et al.
patent: 2006/0241099 (2006-10-01), Mercep et al.
patent: 967573 (1975-05-01), None
patent: 20000310 (2002-02-01), None
patent: 45008611 (1970-02-01), None
patent: WO-01/87890 (2001-11-01), None
patent: WO 91/87890 (2001-11-01), None
Kimoto and Ohta, Synthesis of 10,11-Dihydro-5H-dibenzo[a,d]cycloheptene Derivatives, Yakugaku Zasshi, 1967, 87:861-866.
Van Assche and Rutgeerts, Anti-TNF Agents in Crohn's disease, Exp. Opin. Invest. Drugs, 2000, 9: 103-111.
Pfeffer et al., Mice Deficient for the 55kd Tumor Necrosis Factor Receptor Are Resistant to Endotixic Shock, yet Succumb to L. monocytogenes Infection, Cell, 1993, 73:457-467.
Keffer et al., Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis, EMBO J., 1991, 10:4025-4031.
Georgopoulos et al., Transmembrane TNF Is Sufficient To Induce Localized Tissue Toxicity and Chronic Inflammatory Arthritis in Transgenic Mice, J. Inflamm., 1996, 46:86-97.
Bresnihan, Treatment with Recombinant Human Interleukin-1 Receptor Antagonist (rhlL-1ra) in Rheumatoid Arthritis (RA); Results of a Randomized Double-Blind, Placebo-Controlled Multicenter trial, Arthrit. Rheum., 1996, 39:73.
Mori et al., Attenuation of Collagen-Induced Arthritis in 55-kDa TNF Receptor Type 1 (TNFR1)- lgG1-Treated and TNFR1-Deficient Mice, J. Immunol., 1996, 157:3178-3182.
Elliot et al., Randmoised double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis, The Lancet, 1994, 344:1105-1110.
Carswell et al., An endotoxin-induced serum factor that causes necrosis of tumors, Proc. Natl. Acad. Sci. U.S.A., 1975, 72:3666-3670.
Dinarello, Interleukin-1, Rev. Infect Disease, 1984, 6(1):51-95.
Dinarello, An Update on Human Interleukin-1: From Molecular Biology to Clinical Relevance, J. Clinical Immunology, 1985, 5:287.
Lombardino, Synthesis of Some Novel Tetracyclic Imidazole Derivatives, J Heterocyclic Chem., 1974, 11:17-21.
Cavill, Organic Oxidation Processes, 1955, 4:4426-4429.
Romo et al., Total Synthesis and Immunosuppressive Activity of (-)-Pateamine A and Related Compounds: Implementation of a beta-Lactam-Based Macrocylization, J. Am. Chem. Sco., 1998, 120: 12237-12254.
Badger et al., Pharmacological Profile of SB 203580, a Selective Inhibitor of Cytokine Suppressive Binding Protein/p38 Kinase, in Animal Models of Arthritis, Bone Resorption, Endotoxin Shock and Immune Function, J. Pharmac. Env. Therap., 1996, 279(3):1453-1461.
Collier et al., The Abdominal Constriction Response and Its Suppression By Analgesic Drugs in the Mouse, Br. J. Pharmac. Chemother., 1968, 32:295-310.
Fukawa et al., A Method for Evaluating Analgesic Agents in Rats, J. Pharmacol. Meth., 1980, 4:251-259.
Schweizer et al., Combined automated writhing/motility test for testing analgesics, Agents and Actions, 1988, 23:29-31.
Mattioli and Ghia, omega-Dialkylaminoalkyl Ethers of Phenyl-(5-substituted 1-phenyl-1H-pyrazol-4-yl)methanols with Analgesic and Anti-inflammatory Activity, J. Heterocyclic Chem., 1997, 34:963-968.
Benko Iva
Mercep Mladen
Mesic Milan
Pesic Dijana
GlaxoSmithKline
Grazien Nyeemah
Saeed Kamal A.
Young J. Scott
LandOfFree
1-oxa-3-aza-dibenzoazulenes as inhibitors of tumor necrosis... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 1-oxa-3-aza-dibenzoazulenes as inhibitors of tumor necrosis..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 1-oxa-3-aza-dibenzoazulenes as inhibitors of tumor necrosis... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3851241